The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
J4ams - as someone who has often been called a de-ramper, shorter etc on here, I think you'd have to be blind or wilfully ignorant to not understand that something significant is going on here in the background. Given what we've heard over the last week or so and what we know about Avacta, it's hard to not envisage us being a part of it....
Time will obviously tell.
Simple fact is, if the UK gov are spending the billions quoted on LFT's over the next two quarters, and are insistent on a sovereign supply, then we HAVE to be involved.
Only 3/4 UK co's producing LFT's and to get to the 2m a day figure quoted then all will have to be involved.
It poses more questions than answers as usual..
I think a decent possibility that “LFD x” is our saliva test. Doesn’t help with figuring out where the AN version is though!
Guess we will find out soon enough.
Thanks Richob, although I'm not sure he has? I presume you, and many others here, are of the strong opinion that TT has indeed been complete, and the reason Al has not updated shareholders (as he REPEATEDLY said he would do at this stage), is because of some sort of non-disclosure agreement in place with UK Gov?
Not a deramp etc, genuinely interested as to the consensus view on this point given what the CEO has previously said.
Spot on Wyndrum, we're either on the cusp of massive and transformational news or have made very little progress over the last few months.
All things being equal, I would lean towards the former, but the one thing that bugs me is Al's repeated statements that he would update the market in full with a clear timeline to market once tech transfer has been complete. He has said this multiple times, and given he hasn't done so as of yet, I have a lingering doubt.
Totally agree with the insinuation that it is the IP / platforms that are most relevant to long term value build here.
Proving the effectiveness and reliability of affimers is far more valuable long term then an extra few hundred million quids worth of revenues from a sub standard test.
As I say though, I’d be frankly delighted with £3-5 / share at end of Q1!
Hi Rap, no deliberate misinterpretation meant so apologies if that was the case.
FYI, there’s quite a lot of middle ground between liquidation and the LFT getting to market, clearly I wasn’t suggesting worst case is liquidation.
My view is that £3-5 would actually be a fantastic position in 3 months time. I don’t think we are ever going to see a Mcap of £3.5bn + on covid revenues alone.
Apologies again if the post was misunderstood.
Of course I believe it’s going to come off but that’s not what I referenced...You agree that WORST CASE scenario is a share price of £3-5 in three months time? I’ll have some of what you’re on please !
Surely worst case is LFT not getting to market etc etc, in which case I’ll predict we will be somewhat less than £3...
“I’d like to think you’ll pop back if you were wrong” - huh? I’m invested here, clearly want this to fly, would love to be wrong etc etc. Just found the statement that worst case scenario is that in three months market cap will be higher than ever a slightly bizarre one....
“A rapid point of care test”....no mention of testing at home unless I’m being daft...not that it’s a huge issue currently given POC is first base and hopefully looks like we’re fast approaching it!
In saying all of that, I think it's hard to see us not being taken out by big pharma at some point in the next 2-5 years. If we can get a high quality test out to prove the effectiveness of affirmers and AVA6000 is successful then it's going to be fun and games.
As others have repeatedly said, a lot needs to go tits up for Avacta not to multi bag over the next few years. The IP is the value here.
Fully agree Wyndrum.
No doubt there's still a substantial market there IF Al can finally get a product(s) to market, but to be honest I now see the main goal of the diagnostics side of the business as being a decent cash cow for 12-24months as to fund the therapeutics without any further need for fund raising and dilution.
Bombarding the CEO with emails is futile and a waste of his and our time. However, the investors@avacta email address is a total joke. Have enquired a few times around some clarifications / info requests and have never had a single acknowledgement, let alone a response.
About as useful as Yellow Jersey PR.
Re tests, I think we have to be due some news this month, one way or another.